Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261486 | 0.98 | ALDH1A1 (0.52) | ALDH1A1TDP1MEN1LMNABLM | |
| SCHEMBL6929123 | 0.98 | ALDH1A1 (0.52) | ALDH1A1TDP1MEN1LMNABLM | |
| SCHEMBL8896820 | 0.98 | ALDH1A1 (0.52) | ALDH1A1TDP1MEN1LMNABLM | |
| SCHEMBL2460940 | 0.93 | — | — | |
| SCHEMBL8399806 | 0.93 | — | — | |
| SCHEMBL6384594 | 0.83 | — | — | |
| SCHEMBL9052189 | 0.83 | — | — | |
| SCHEMBL20641014 | 0.83 | — | — | |
| SCHEMBL8466548 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TDP1MEN1LMNABLM | |
| SCHEMBL6931009 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPTTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0976734-B1 | Selective inhibitors of viral or bacterial neuraminidase | GILEAD SCIENCES INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050176758-A1 | 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors | GILEAD SCIENCES, INC. | 2005-08-11 | — | — | US | disclosed |
| US-6225341-B1 | FOR INHIBITING NEURAMINIDASE; FOR THERAPY AND PROPHYLAXIS OF VIRUS INFECTION | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0759917-B1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES INC (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176758-A1 | 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors | NEU3, NEU1, NEU4 | ALDH1A1 374/4885TDP1 2496/4885MEN1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.